Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
HRMY
#1797
Harmony Biosciences Holdings, Inc. Common Stock
28.540
0
+0.25%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+0.25%
Monatliche Änderung
-24.24%
6 month change
-7.64%
Jahresänderung
-7.64%
Vorheriger Schlusskurs
28.470
0
Open
28.540
0
Bid
Ask
Low
28.540
0
High
28.540
0
Volumen
110
Märkte
Aktien
Gesundheitswesen
HRMY
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
56.89 M
58.87 M
59.62 M
56.77 M
57.35 M
57.84 M
—
Valuation ratios
Enterprise value
1.83 B
2.28 B
2.91 B
1.44 B
1.52 B
1.41 B
5.04 B
Price to earnings ratio
14.58
73.52
17.83
14.46
13.71
13.81
45.34
Price to sales ratio
5.83
8.27
7.39
3.19
2.79
2.52
9.44
Price to cash flow ratio
-312.12
25.61
22.4
8.47
9.06
6.29
27.43
Price to book ratio
9.59
13.54
8.03
3.98
3.02
2.52
4.49
Enterprise value to EBITDA ratio
61.68
20.96
20.12
6.62
7.12
6.1
20.5
Profitability ratios
Return on assets %
0.09
0.08
0.27
0.16
0.15
0.12
0.14
Return on equity %
0.38
0.19
0.45
0.28
0.22
0.18
0.2
Return on invested capital %
25.57
193.23
56.92
157.94
129.43
141.66
124.81
Gross margin %
82.64
81.82
80.93
79.17
78.06
77.16
310.62
Operating margin %
10.63
28.66
27.45
32.99
26.7
24
97.64
EBITDA margin %
18.55
35.56
33.07
37.27
29.85
26.65
115.7
Net margin %
23.13
11.33
41.44
22.14
20.36
18.27
74.97
Liquidity ratios
Quick ratio
1.93
5.21
5.02
2.72
3.27
3.58
14.74
Current ratio
1.95
5.29
5.07
2.75
3.31
3.6
14.86
Inventory turnover
7.26
13.45
19.13
25.1
24.97
31.6
31.21
Asset turnover
0.37
0.71
0.79
0.78
0.79
0.76
0.77
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.45
0.44
0.28
0.22
0.16
0.11
0.52
Long term debt to total equity ratio
2
1.02
0.47
0.38
0.25
0.17
0.76
Per share metrics
Operating cash flow per share
0.12
1.66
2.36
3.63
3.8
5.95
5.95
EBIT per share
0.66
1.48
1.97
3.18
3.3
3.56
3.56
EBITDA per share
1.15
1.83
2.37
3.59
3.69
3.95
4.26
Total debt per share
—
—
—
—
—
—
—
Cash per share
8.87
3.96
5.29
5.85
8.07
13.24
43.04
Net current asset value per share
10.2
4.8
6.55
7.47
10.01
15.49
52.59
Tangible book value per share
-2.53
0.72
3.96
5.46
9.43
13.34
47.91
Working capital per share
4.98
3.9
5.26
4.76
6.98
11.19
38.41
Book value per share
3.77
3.15
6.59
7.74
11.39
14.86
54.63
Nachrichten
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Corcept's Q4 Earnings and Revenues Fall Short of Estimates
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Früherer Generika-Start für Wakix: UBS senkt Kursziel für Harmony Biosciences
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry
Truist bestätigt "Halten"-Rating für Harmony Biosciences mit Kursziel von 25 US-Dollar
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market